表紙
市場調查報告書
商品編碼
721709

關鍵意見領袖 (KOL)的見解:發炎性腸道疾病 (IBD) 治療藥的etrolizumab──第三階段的臨床實驗資料

KOL Perspectives: Views on initial Phase III data for etrolizumab in IBD

出版日期: | 出版商: GlobalData | 英文 27 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告彙整產業關鍵意見領袖 (KOL) 的訪談調查結果,提供「UEGW 2017」(歐洲消化器官病周) 所發表的發炎性腸道疾病 (IBD) 和克隆氏症,潰瘍性大腸炎 (UC)上治療藥etrolizumab臨床實驗資料──特別是第三階段的臨床實驗資料結果──相關資料。

目錄

  • 摘要整理
  • 背景情況
  • 研究小組組成
  • 調查結果及其意義

附錄

目錄
Product Code: GDHC049SP

This KOL Insight briefing focuses on KOL views on etrolizumab Phase III data presented at UEGW 2017 in both Crohn's disease and UC.

The briefing includes analysis of KOL opinion on the following topic areas -

  • Views on etrolizumab Phase III efficacy data in Crohn's disease
  • Expected use of etrolizumab in Crohn's disease
  • Views on etrolizumab Phase III efficacy data in UC
  • Expected use of etrolizumab in UC>Improving Trial Enrollment

Key Highlights

  • Broadly positive KOLs suggest etrolizumab Phase III data is an improvement on vedolizumab (VDZ) Phase III results Crohn's disease
  • Majority of KOLs view etrolizumab's efficacy to be comparable to VDZ, but consider its efficacy as inferior to anti-TNFs
  • Majority of KOLs expect to use etrolizumab as a second/third-line therapy in the Crohn's disease treatment algorithm.

Scope

  • The insight briefing is based on Sociable Pharma's analysis of primary research with our inflammatory bowel disease key opinion leaders (KOLs)
  • In total, we conducted interviews with 10 KOLs: 5 Europe-based & 5 N. America-based
  • Interviews performed during December 2017
  • KOL data is analyzed to produce: Charts summarizing KOL opinions
  • Chart call-outs of key information & details
  • KOL quotes
  • Summary of KOL reporting trends
  • Insight from Sociable Pharma's analysts.

Reasons to buy

  • Combines Qualitative & semi-quantitative insight from key opinion leaders on "etrolizumab Phase III data in UC & Crohn's disease"
  • Includes insight & recommendations from our disease-specific healthcare analysts
  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD
  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Table of Contents

  • Executive Summary
  • Background
  • Research Panel Composition
  • Results & Implications

Appendix